Plain-English translation of NCT05300035 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study tests whether adding two long-acting broadly neutralizing antibodies—3BNC117-LS and 10-1074-LS—to standard HIV treatment during the earliest stage of infection can help your body fight HIV better in the long run. You'll receive this medication alongside regular antiretroviral therapy (the standard HIV drugs), and researchers will study whether this combination gives your immune system better control over the virus.
Most people with HIV need to take medications for life to keep the virus under control. This trial is exploring whether jumpstarting your immune system with these special antibodies early in infection might allow some people to eventually stop taking daily HIV drugs and still keep the virus in check.
You likely qualify if…
You likely don't qualify if…
You will start standard HIV medication right away. Alongside this, you'll receive infusions of either the experimental antibodies or a placebo (saline solution) over the first year. After 52 weeks, you and your doctors will stop HIV medications together (called a treatment interruption) to see how well your immune system can control the virus on its own. You'll have regular clinic visits for blood tests and monitoring, with the total study duration varying based on when your viral levels start to rebound.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
France